FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

May 31, 2013

Study Completion Date

July 31, 2014

Conditions
Gastroesophageal CancerGastric Cancer
Interventions
DRUG

FOLFOX

Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours

DRUG

bevacizumab

bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy

Trial Locations (2)

Unknown

Medical Oncology & Hematology PC, Hamden

06520

Yale University School of Medicine, New Haven

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Yale University

OTHER

NCT00673673 - FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer | Biotech Hunter | Biotech Hunter